Cardiac implantable electronic device use is increasing worldwide. Improvements in medical therapy will result in many patients requiring subsequent procedures for generator replacement or "upgrades" to multilead systems. Although data from retrospective series have been available, REPLACE is the first prospective multicenter trial to examine complications related to generator replacement. The 2 patient populations studied included patients who needed only a generator replacement and those who required a lead addition or revision for advanced therapy. This study examined a broad range of major and minor complications. Major complications with planned generator replacements alone were modest; however, when a transvenous lead addition or revision was combined with a generator replacement, the risk was markedly higher, especially for left ventricular leads. Our results support the use and development of devices with long battery life to minimize the lifetime surgical risk for a patient. The choice of device for each patient must be carefully considered. Mitigation of lead-related risks is also important. Using the fewest leads necessary for the clinical need of the patient is critical. The risk associated with upgrade procedures is concerning and favors performing indicated complex procedures before the development of advanced end-stage medical and cardiac disease, situations in which the risk may be prohibitive. Finally, our results provide insight into procedural outcomes for the next phase of life for patients who receive cardiac implantable electronic devices and a more robust analysis that can be used to establish a benchmark for comparative performance in this time of healthcare reform. See p 1553.
Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
Cardiac energy impairment is a consistent feature of hypertrophic cardiomyopathy and precedes the development of hypertrophy. We hypothesized that this energy deficiency plays a key role in the pathophysiology of exercise limitation via impairment of the highly energy-dependent process of left ventricular active relaxation on exercise. To test this hypothesis, we assessed whether the metabolic modulator perhexiline augmented myocardial energetics in hypertrophic cardiomyopathy and whether this translated into improved physiological and clinical outcomes in a randomized, double-blind, placebo-controlled study. In accordance with previous studies, the hypertrophic cardiomyopathy patients in the present study, who were symptomatic but manifested no left ventricular outflow tract obstruction, had a significantly decreased myocardial energy charge as assessed by 31 P magnetic resonance spectroscopy; this was accompanied by a paradoxical dynamic slowing of myocardial relaxation during exercise. Perhexiline improved myocardial energetics, normalized the impairment of dynamic myocardial relaxation, and improved both patient symptoms and exercise capacity. The results of the present study support the hypothesis that energy deficiency contributes to the pathophysiology of exercise limitation in hypertrophic cardiomyopathy and that augmenting myocardial energetics through metabolic modulation may be a novel and potentially effective therapy for the management of symptomatic hypertrophic cardiomyopathy in patients without left ventricular outflow tract obstruction, although this requires confirmation in a larger study. The therapeutic potential is especially important in this group of patients in whom treatment options are limited. See p 1562.
Outcomes After Acute Myocardial Infarction in South Asian, Chinese, and White Patients
In this observational study using administrative hospital data in an equal-access healthcare system, there were striking differences in outcomes among South Asian, Chinese, and white patients after acute myocardial infarction. South Asian patients had substantially lower long-term mortality after acute myocardial infarction compared with white patients. Short-term mortality among Chinesedescent patients was significantly higher than their white counterparts. The higher early mortality among Chinese patients cannot be fully explained by increased cardiovascular risk factors and advanced age at the time of presentation. The higher short-term mortality requires closer examination of the severity of infarction and acute care processes in this ethnic population. Although international studies consistently show that South Asian patients have a higher cardiovascular mortality compared with other groups, we found no difference in short-term mortality and significantly lower long-term mortality after acute myocardial infarction among South Asian compared with white patients. These findings highlight the importance of comparing ethnic groups within the same equal-access healthcare system. These findings also suggest that higher global cardiovascular mortality observed among South Asian patients may reflect a higher prevalence of coronary disease, higher rates of out-of-hospital acute myocardial infarction, or regional differences in cardiac care rather than inherently poor outcomes after hospitalization for acute myocardial infarction among South Asians. See p 1570.
In Vivo Therapeutic Gas Delivery for Neuroprotection With Echogenic Liposomes
Stroke is the third leading cause of death and the most common cause of adult disabilities in the United States. The emergent treatment of acute ischemic stroke has 2 primary goals: rapid restoration of cerebral blood flow (reperfusion) and limitation of neural injury (neuroprotection). Although many therapeutic strategies have demonstrated pharmacological effect for neuroprotection including their ability to decrease stroke size, these strategies often fail when translated to the clinical setting. Inability to deliver high local doses sufficiently to the ischemic area and inadequate penetration of therapeutic agents across the blood-brain barrier are major contributory factors. The present study suggests that intravenous delivery of a noble gas, xenon, which readily diffuses across the blood-brain barrier, with the use of a delivery vehicle (liposomes) and a release mechanism (ultrasound), enhances local xenon delivery and decreases stroke size. Site-specific payload release from liposomes can be controlled by low-power ultrasound over the common carotid artery with enhanced neuroprotective delivery to the ischemic circulation. This study demonstrates that both intra-arterial and intravenous carrier deliveries with low-power ultrasound activation over the common carotid artery have the same therapeutic effect for neuroprotectant payload delivery to the cerebral ischemic area. Together, this novel delivery vehicle and delivery methodology have the potential to provide a clinically effective and efficient means for therapeutic gas/pharmaceutical delivery for improved stroke treatment. See p 1578.
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Conditional Overexpression of Neuronal Nitric Oxide Synthase Is Cardioprotective in Ischemia/Reperfusion
Myocardial ischemia is the major threat to cardiac myocytes in acute myocardial infarction. Yet, despite infarct-sparing interventions like early reperfusion therapy by percutaneous coronary intervention, myocardial scars develop, even if call-to-balloon time is Ͻ90 minutes. Therefore, there is a medical need for additional options to enhance myocardial resistance to ischemia. Ischemic preconditioning or drugs that stimulate cardioprotective signaling (pharmacological preconditioning) might prove to be beneficial in this setting. Endothelial nitric oxide synthase (NOS) and inducible NOS have already been proven to be cardioprotective in ischemia/reperfusion experiments. We now add data on the remaining NOS isoform, neuronal NOS (or NOS1). Neuronal NOS overexpression in an animal model restored myocardial function compared with wild-type mice after reperfusion caused by inhibition of xanthine oxidoreductase (which decreased reactive oxygen series formation) and by inhibition of cytochrome c oxidase (which decreased myocardial oxygen consumption). It appears that transgenic overexpression in the myocardium of each of the 3 NOS isoforms acts as a net and prevents reperfusion damage, at least in part. However, the precise molecular mechanism behind each isoform is probably different, depending on the subcellular localization of each isoform. It has also been demonstrated that neuronal NOS may inhibit arrhythmogenesis by maintaining intracellular Ca 2ϩ homeostasis in cardiomyocytes via S-nitrosylation of Ca 2ϩ -handling proteins, leading to reductions in ventricular arrhythmias and death after myocardial infarction. Hence, adding NO as a drug to the therapeutic regimen in acute myocardial infarction is likely to be less successful than increasing neuronal NOS expression in the myocardium. See p 1588.
Pediatric Metabolic Syndrome Predicts Adulthood Metabolic Syndrome, Subclinical Atherosclerosis, and Type 2 Diabetes Mellitus but Is No Better Than Body Mass Index Alone: The Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study
In a recent Scientific Statement from the American Heart Association on metabolic syndrome (MetS) in children and adolescents, the need for additional research examining the efficacy of pediatric MetS to predict adult health was highlighted. In the present analyses based on 2 population-based prospective cohorts, the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study, we examined the utility of youth MetS and its components in predicting adult high carotid intima-media thickness and type 2 diabetes mellitus among 1781 participants aged 9 to 18 years at baseline who were reexamined 14 to 27 years later. We observed that youth with MetS were at 2 to 3 times the risk of having high carotid intima-media thickness and type 2 diabetes mellitus as adults compared with those free of MetS. However, the prediction of adult high carotid intima-media thickness and type 2 diabetes mellitus with the use of youth body mass index was either equivalent or superior to classification based on pediatric MetS. Our findings have direct clinical relevance because they suggest that in the clinical setting, efforts to identify youth with heightened future risk of meaningful outcomes can be minimally achieved with the use of body mass index only, thus avoiding cost and other barriers associated with testing and classification of youth MetS. However, clinicians who use high body mass index to identify youth at increased future risk need to keep in mind that a large proportion of contemporary youth will be classified as at risk and that our analyses are unable to discount that youth MetS may be useful in identifying and possibly treating other cardiometabolic disorders. See p 1604.
Enhanced External Counterpulsation Improves Peripheral Artery Flow-Mediated Dilation in Patients With Chronic Angina: A Randomized Sham-Controlled Study
Not all patients with symptomatic coronary artery disease are amenable to standard revascularization procedures because of unsuitable coronary anatomy, multiple previous revascularization attempts, age, additional comorbid conditions, or patient preference. Such difficult cases require physicians to entertain other options. In the United States alone, Ͼ2.5 million patients with coronary artery disease are not amenable to bypass or angioplasty. For those patients in whom repeat (or initial) revascularization procedures are not appropriate and in whom aggressive medical therapy fails to reduce anginal pain, the search for additional therapeutic options continues. New treatment modalities, which are at various stages of clinical evaluation, include minimally invasive bypass surgery, spinal cord stimulation, transcutaneous electric nerve stimulation, transmyocardial laser revascularization, and enhanced external counterpulsation (EECP). Of these modalities, EECP is the only truly noninvasive, atraumatic technique for which a reduction of angina symptoms and nitrate use, increased exercise tolerance, and an improvement in objective measures of myocardial ischemia have been shown. The present study was the first randomized sham-controlled investigation to focus on peripheral vascular mechanisms that may contribute to the clinical benefits of EECP treatment. In a cohort of patients with symptomatic coronary artery disease (nϭ42), EECP reduced anginal episodes, nitrate usage, and Canadian Cardiovascular Society angina classification. EECP elicited commensurate improvements in peripheral artery vasodilatory capacity and increases in plasma levels of endothelial-derived vasoactive agents. These novel findings support the hypothesis that EECP improves peripheral endothelial function in patients with symptomatic function and may reduce myocardial oxygen demand. See p 1612.
Chemokine Receptor 7 Knockout Attenuates Atherosclerotic Plaque Development
Modulation of both innate and adaptive immune responses has become an attractive and, in some clinical settings, successful tool to treat a variety of diseases (eg, rheumatic arthritis and different forms of cancer). The perception that the interaction between innate and adaptive immunity is also important for the development of atherosclerosis has already resulted in some attempts to influence atherosclerotic plaque development by immunomodulation. Our study strengthens the importance of secondary lymphoid organs and the impact of T-cell recirculation for the transition from innate to adaptive immune system activation during atherogenesis. Together with the fact that our findings, together with others, underline the antigenic potential of oxidized low-density lipoprotein, the study presented may lead the way to novel therapeutic strategies to fight the detrimental clinical end points of atherosclerosis. For instance, blockage of costimulatory molecules on oxidized low-density lipoprotein-pulsed dendritic cells ex vivo might positively influence atherosclerotic plaque development. In addition, artificial modulation of oxidized low-density lipoprotein presentation or interaction of dendritic cells with T cells in secondary lymphoid organs may be new ways to attenuate atherogenesis. See p 1621.
